

AETERDERM®

PURILAX *with Lidocaine*

Cross-Linked Hyaluronic Acid



PURILAX Sub-Q	
PURILAX Deep	
PURILAX Fine	

AETERDERM®

PURILAX

with Lidocaine

Cross-Linked Hyaluronic Acid

Soft, Uniform gel type, Easier to mold to achieve Natural results

- 24mg of highest purified HA content
- Optimized viscoelasticity for stylish molding
- Unified particle implementation technology
- Less than 0.025EU Endotoxin unit level
- User-friendly injection pressure

 **PURILAX Sub-Q**



 **PURILAX Fine**



 **PURILAX Deep**



AETERDERM®

PURILAX

with Lidocaine



The Ultimate Soft & Durable Monophasic Hyaluronic gel

(PURILAX Filler)



Stable and Uniform Cross-linking


Optimized Viscoelasticity

High Cohesivity

Flexible Plasticity


- ⦿ PURILAX Hyaluronic acid gel is manufactured by using a special grinding machine for consistent injection.

PURILAX Shape Maintenance Test

AETERDERM® PURILAX	(A Product)	(B Product)
 Before	 Before	 Before
 12 hours after	 12 hours after	 12 hours after
 48 hours after	 48 hours after	 48 hours after

- ⦿ PURILAX dermal fillers are manufactured using our latest Cross-Linking Technology to create a monophasic, cohesive, polydensified matrix.
- ⦿ This provides significant results, especially in the treatment of patients with extremely deep folds.
- ⦿ The unique structure of these PURILAX cross-linking hyaluronic acid molecules also improves the efficacy and tolerability of PURILAX, resulting in a smooth, natural look and feel post-injection.

Product Range

	PURILAX Sub-Q	1.1 mL x 1 Syringe / Box
	Hyaluronic Acid Concentration (mg/mL) Lidocaine Content (mg/mL) MOD (Degree of Modification, mol %) Gel Type Storage Modulus (G') Complex Viscosity Injection Force (N) (30G UTW) Injection Depth Duration Enclosed Needle Gauge	24mg 3mg (0.3%) 4.35% Monophasic 250 - 350 G' 300 - 500 pa 35.3 N Subcutaneous 18 months Needle 2 X 25G * 1/2"
	PURILAX Deep	1.1 mL x 1 Syringe / Box
	Hyaluronic Acid Concentration (mg/mL) Lidocaine Content (mg/mL) MOD (Degree of Modification, mol %) Gel Type Storage Modulus (G') Complex Viscosity Injection Force (N) (30G UTW) Injection Depth Duration Enclosed Needle Gauge	24mg 3mg (0.3%) 2.85% Monophasic 150 - 200 G' 200 - 300 pa 27.2 N Mid dermis 12 months Needle 2 X 27G * 1/2"
	PURILAX Fine	1.1 mL x 1 Syringe / Box
	Hyaluronic Acid Concentration (mg/mL) Lidocaine Content (mg/mL) MOD (Degree of Modification, mol %) Gel Type Storage Modulus (G') Complex Viscosity Injection Force (N) (30G UTW) Injection Depth Duration Enclosed Needle Gauge	24mg 3mg (0.3%) 1.75% Monophasic 30 - 100 G' 100 - 200 pa 14.9 N Superficial - Mid dermis 12 months Needle 2 X 30G * 1/2"

Rheological Profile

(Parameter)	(Standard)	(Result)
Appearance	Transparent and colorless viscous liquid with no foreign substances	Satisfied
pH	6.8 ~ 7.5	6.83
BDDE Residue	Maximum 2.0ppm	0 ppm
Heavy Metal	Maximum 10.0ppm	Below 10.0ppm
Osmotic Pressure	200 ~ 400 mmol/kg	318mmol/kg
Volume	Minimum 1.0mL	1.07~1.09mL
Aseptic / Toxic	Aseptic / Toxic	Satisfied
Endotoxin	Below 12.5 EU/mL	Below 0.02 EU/mL

Effectiveness


(Viscoelasticity)



The role of hyaluronic acid is to increase moisture, retain collagen, and provide elasticity and flexibility.

- ⦿ High viscoelasticity allows to maintain good volume for long duration.

(Exceptional Volumizing Capacity)



(Proven Biocompatibility)

- ◎ PURILAX uses only the highest-grade raw materials to preserve natural skin integrity and allow products to distribute evenly in connective tissue with the minimum probability of causing inflammatory cells.
- ◎ PURILAX has a great biointegration and high tolerability profile and has been verified to be endotoxin-free and BDDE-free.
- ◎ Their safety has also been confirmed by the biocompatibility tests conducted according to the ISO classification.

(Analysis Condition)

Analysis Equipment	Anton Paar Model : MCR 302e / Serial No : 84364401
Target temperature	25°C
Start frequency	0.01 Hz
End frequency	10 Hz
Shear strain	1.0%
Samples per decade	11

PURILAX Sub-Q	
PURILAX Deep	
PURILAX Fine	



(Comparison)

Hyaluronic acid gels are commonly injected into the skin to improve facial appearance. The different processes used in their manufacture and formulation generate products with unique rheological properties that play an important role in their clinical performance.

These three rheological properties are the most important in determining the performance of hyaluronic acid:




Cohesivity	For excellent tissue integration
Viscoelasticity	For optimal tissue support
Plasticity	For excellent cohesivity

(Cohesivity)

- ⦿ PURILAX's unique viscoelastic properties and variable density allow for homogeneous soft tissue augmentation and rejuvenation.
- ⦿ The PURILAX range integrates naturally into the skin to produce predictable and natural results.
- ⦿ These optimized rheological properties result in seamless dermal integration.

Convenience Extrusion Force

A consistent extrusion force allows for a smooth and convenient injection.



References) Manufacturer research institute

Before & After

(Crow’s feet & Eye area)



- Used Product
PURILAX Fine
- Used Needle Gauge
30G
- Injection Amount
2.2 cc
- Patient's Age
38 years old

References) Clinical trials by Dermatol Ther 2022;19:28-29

NOTE) After the procedure, the shallow and long wrinkles under the eyes were noticeably improved, and the deep crow's feet wrinkles had the greatest improvement. By injecting small-molecule HA(PURILAX Fine filler), it was confirmed that hydration also improved overall skin radiance and blotchy redness.

(Fullness of lips)



- Used Product
PURILAX Deep
- Used Needle Gauge
27G
- Injection Amount
1.1 cc
- Patient's Age
29 years old

References) Clinical trials by Dermatol Ther 2022;27:37-38

NOTE) After one week of injection of medium-sized molecule HA (PURILAX Deep filler) into the lip area, the filler molecules were stably and naturally positioned in the lip dermis tissue, and no significant toxic reactions were observed.

(Forehead wrinkles & volumizing)




- Used Product
PURILAX Sub-Q
- Used Needle Gauge
25G
- Injection Amount
4.4 cc
- Patient's Age
32 years old

References) Clinical trials by Dermatol Ther 2022;31:43-48


NOTE) Large-molecule HA (PURILAX Sub-Q filler) was injected into a 32-year-old female patient to improve severe to moderate forehead wrinkles. After ten days, the HA gel that had settled subcutaneously was stable and natural, and no noticeable deformation was observed after the procedure.

Indication


PURILAX Sub-Q



PURILAX Deep



PURILAX Fine



AETERDERM®

PURILAX

with Lidocaine

Cross-Linked Hyaluronic Acid

(Composition)

Cross-linked hyaluronic acid	24mg/mL
Lidocaine HCl	0.3mg/mL
Phosphate-buffered saline	q.s.

(Package Unit)

1 Pre-Filled-Syringe and 2 Needles / 1 Box

(Storage)

Room Temperature (1°C~30°C), Avoid Light and Freezing

